Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade F 6.04 2.37% 0.14
NVAX closed up 2.37 percent on Monday, May 20, 2019, on 1.29 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NVAX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 2.37%
Stochastic Reached Oversold Weakness 2.37%
Wide Bands Range Expansion 2.37%
Down 3 Days in a Row Weakness 2.37%
Oversold Stochastic Weakness 2.37%

Older signals for NVAX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Influenza Vaccination Vaccines Influenza Vaccine Rabies Seasonal Influenza H5n1 Clinical Trials Virus Like Particle
Is NVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 51.6
52 Week Low 5.72
Average Volume 1,034,987
200-Day Moving Average 29.4463
50-Day Moving Average 10.0014
20-Day Moving Average 8.4367
10-Day Moving Average 6.781
Average True Range 0.9043
ADX 30.5
+DI 19.6162
-DI 25.6458
Chandelier Exit (Long, 3 ATRs ) 8.2871
Chandelier Exit (Short, 3 ATRs ) 8.4329
Upper Bollinger Band 11.9858
Lower Bollinger Band 4.8876
Percent B (%b) 0.16
BandWidth 84.134792
MACD Line -1.6296
MACD Signal Line -1.5772
MACD Histogram -0.0524
Fundamentals Value
Market Cap 1.75 Billion
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -7.84
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.87
Resistance 3 (R3) 6.91 6.68 6.73
Resistance 2 (R2) 6.68 6.47 6.66 6.68
Resistance 1 (R1) 6.36 6.34 6.52 6.32 6.64
Pivot Point 6.13 6.13 6.21 6.11 6.13
Support 1 (S1) 5.81 5.92 5.97 5.77 5.44
Support 2 (S2) 5.58 5.79 5.56 5.40
Support 3 (S3) 5.26 5.58 5.35
Support 4 (S4) 5.22